ADAM28 is a serological and histochemical marker for non-small-cell lung cancers

✍ Scribed by Hiroaki Kuroda; Satsuki Mochizuki; Masayuki Shimoda; Miyuki Chijiiwa; Kazunori Kamiya; Yotaro Izumi; Masazumi Watanabe; Hirohisa Horinouchi; Masahumi Kawamura; Koichi Kobayashi; Yasunori Okada

• Publisher: John Wiley and Sons
• Year: 2010
• Tongue: French
• Weight: 815 KB
• Volume: 127
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.25212

✦ Synopsis

Abstract

ADAM28 (a disintegrin and metalloproteinase 28) is over‐expressed in non‐small‐cell lung cancer (NSCLC) with correlation to cancer cell proliferation, tumor size and lymph node metastasis. The present study was aimed to develop an enzyme‐linked immunosorbent assay (ELISA) system for diagnosis and monitoring of NSCLC. Our ELISA specifically measured ADAM28, showing negligible cross‐reactivity with other metalloproteinases. The ADAM28 level in the NSCLC tissue was remarkably 36.9‐fold higher than that in the non‐neoplastic lung tissue (p < 0.001). The serum level was significantly 4.6‐fold higher in the NSCLC patients (5.41 ± 8.62 ng/ml; n = 102) than in the control subjects (1.17 ± 0.93 ng/ml; n = 20) (p < 0.001), and increased with progress of tumor stage (p < 0.001). The level was also significantly higher in the patients with recurrent carcinoma than the control (p < 0.001) and in the patients with lymph node metastasis than those without metastasis (p < 0.001). The sensitivity, false‐negative rate and AUC for ADAM28 were better than those for carcinoembryonic antigen. The combination of both assays improved the sensitivity, specificity, false‐positive and false‐negative rates for NSCLC. There was a positive correlation between the ADAM28 level measured by ELISA system and the degree of immunostaining in the lung adenocarcinomas with a size of ≤20 mm in diameter. The adenocarcinoma patients showing the high immunohistochemical reaction exhibited a poorer disease‐free survival than those with the lower immunoreactivity (n = 102; p < 0.05). These data demonstrate that our ELISA is specific and sensitive to monitor the levels of ADAM28 in the samples from NSCLC patients and suggest that ADAM28 is a useful serological and histochemical marker for NSCLC.